MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Cytek Biosciences Inc

Закрыт

СекторЗдравоохранение

3.99 2.05

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3.85

Макс.

4.07

Ключевые показатели

By Trading Economics

Доход

8.7M

9.6M

Продажи

-18M

34M

Прибыль на акцию

0.116

Рентабельность продаж

28.655

Сотрудники

648

EBITDA

-5.5M

-2.5M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+81.89% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

7 мая 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-159M

514M

Предыдущая цена открытия

1.94

Предыдущая цена закрытия

3.99

Новостные настроения

By Acuity

60%

40%

332 / 386 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Weak Bearish Evidence

Cytek Biosciences Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

2 апр. 2025 г., 23:55 UTC

Популярные акции

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 апр. 2025 г., 22:50 UTC

Главные движущие силы рынка

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 апр. 2025 г., 21:08 UTC

Отчет

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 апр. 2025 г., 21:00 UTC

Отчет

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 апр. 2025 г., 23:56 UTC

Обсуждения рынка

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 апр. 2025 г., 23:44 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

2 апр. 2025 г., 23:44 UTC

Обсуждения рынка

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 апр. 2025 г., 23:44 UTC

Главные новости

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 апр. 2025 г., 23:32 UTC

Обсуждения рынка

Market Talk Roundup: Latest on U.S. Politics

2 апр. 2025 г., 23:32 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

2 апр. 2025 г., 23:32 UTC

Обсуждения рынка

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 апр. 2025 г., 23:12 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

2 апр. 2025 г., 23:12 UTC

Обсуждения рынка

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 апр. 2025 г., 23:10 UTC

Обсуждения рынка

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 апр. 2025 г., 23:09 UTC

Обсуждения рынка

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 апр. 2025 г., 23:09 UTC

Обсуждения рынка

Market Talk Roundup: Latest on U.S. Politics

2 апр. 2025 г., 22:57 UTC

Обсуждения рынка

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 апр. 2025 г., 22:56 UTC

Обсуждения рынка

Market Talk Roundup: Latest on U.S. Politics

2 апр. 2025 г., 22:56 UTC

Обсуждения рынка

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 апр. 2025 г., 22:43 UTC

Главные новости
Приобретения, слияния, поглощения

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 апр. 2025 г., 22:12 UTC

Обсуждения рынка

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 апр. 2025 г., 21:48 UTC

Главные новости

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 апр. 2025 г., 21:41 UTC

Обсуждения рынка

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 апр. 2025 г., 21:17 UTC

Обсуждения рынка

Market Talk Roundup: Latest on U.S. Politics

2 апр. 2025 г., 21:17 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

2 апр. 2025 г., 21:17 UTC

Обсуждения рынка

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 апр. 2025 г., 21:04 UTC

Главные новости

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 апр. 2025 г., 21:03 UTC

Обсуждения рынка

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 апр. 2025 г., 20:53 UTC

Отчет

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 апр. 2025 г., 20:52 UTC

Отчет

Kaiser Aluminum Changes Inventory Acctg Methodology

Сравнение c конкурентами

Изменение цены

Cytek Biosciences Inc Прогноз

Целевая цена

By TipRanks

81.89% рост

Прогноз на 12 месяцев

Средняя 7.13 USD  81.89%

Максимум 9 USD

Минимум 4.5 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для Cytek Biosciences Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

4 ratings

2

Покупка

1

Удержание

1

Продажа

Техническая оценка

By Trading Central

3.9 / 4.06Поддержка и Сопротивление

Краткосрочная

Weak Bearish Evidence

Среднесрочная

Strong Bearish Evidence

Долгосрочная

Strong Bearish Evidence

Настроения

By Acuity

332 / 386Рейтинг в Здравоохранение

Новостные настроения

Свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.